GLP-1 Weight-Loss Drugs Are Reshaping Employer Health Plan Budgets
It was only a few years ago that GLP-1 receptor agonists were a niche treatment category, mostly associated with managing type 2 diabetes. Today, drugs like Wegovy and Zepbound have become one of the most significant cost drivers in employer-sponsored health benefits — and a new report confirms the trend is accelerating. According to data released by plan administrator Benefitfocus, GLP-1 medications now account for more than 20% of total prescription drug spending at large self-insured employer health plans, a milestone that signals a fundamental shift in how American companies budget for employee healthcare.
What the Benefitfocus Report Reveals
The Benefitfocus State of Employee Benefits Report 2026 analyzed data from 316 employers covering 1.8 million employees, focusing specifically on self-insured plans that covered at least 1,000 full-time employees. The findings paint a clear picture of a category that is growing faster than nearly any other in the prescription drug landscape.
Approximately 6% of plan enrollees used a GLP-1 agonist — such as Wegovy, Zepbound, or a comparable medication — for weight management purposes. That figure is up from 5.1% in 2024, representing meaningful year-over-year growth in utilization. More striking, however, is the spending side of the equation: GLP-1 drugs accounted for 20.3% of total prescription spending across the plans surveyed, rising sharply from 17.5% the previous year.
For context, covering a single enrollee on a GLP-1 medication cost these plans an average of $7,400 per year. Multiply that across even a modest-sized workforce and the financial implications become immediately apparent. For large employers, this is no longer a line item that can be quietly absorbed — it demands strategic attention.
Why GLP-1 Usage Keeps Climbing
The rise in GLP-1 utilization is not happening in a vacuum. Two key forces are pushing demand higher, and employers need to understand both in order to manage their exposure effectively.
First, the U.S. Food and Drug Administration expanded the approved indications for GLP-1 medications to include the treatment of cardiovascular disease. This regulatory expansion means that more patients now have a medically documented reason to use these drugs, making it harder for employers and insurers to deny coverage on the grounds of it being a lifestyle or cosmetic treatment. Heart disease remains the leading cause of death in the United States, so this approval has broad reach across plan populations.
Second, Benefitfocus analysts pointed directly to "aggressive direct-to-consumer marketing that has fueled member demand." Pharmaceutical manufacturers have invested heavily in advertising campaigns for GLP-1 medications, making brand names like Ozempic and Wegovy household terms. When employees see these drugs promoted on television and social media, they bring that awareness to their doctors and, ultimately, to their benefits claims. Consumer-driven demand for prescription drugs is not new, but the scale of GLP-1 marketing is exceptional.
The Bigger Picture: A Multi-Billion Dollar National Spending Question
When you zoom out from employer-sponsored plans and look at the broader U.S. population, the numbers become staggering. Approximately half of all Americans are currently overweight or obese, representing the core target population for weight-loss medications. If GLP-1 usage rates seen in large employer plans — around 6% — were applied to the roughly 270 million adult Americans, and if each patient costs an average of $7,400 per year, total U.S. GLP-1 spending in 2025 could approach $120 billion annually.
That projection comes with important caveats. Americans outside of large employer-sponsored plans are generally less likely to have had comprehensive GLP-1 coverage in 2025, and the Benefitfocus analysis may not capture individuals who paid entirely out of pocket. Still, even a conservative estimate underscores that GLP-1 drugs represent one of the most consequential shifts in pharmaceutical spending in modern history.
What This Means for Employers Managing Benefits Costs
For HR leaders, benefits managers, and CFOs at large organizations, the GLP-1 cost trend raises urgent strategic questions. Simply offering coverage without guardrails is increasingly difficult to justify when a single drug category consumes one-fifth of the entire prescription drug budget. At the same time, restricting or eliminating coverage carries its own risks, including employee dissatisfaction, potential legal exposure as FDA indications expand, and the possibility of missing genuine health outcomes benefits — particularly given the cardiovascular approval.
Many employers are exploring a range of management strategies in response, including:
- Implementing prior authorization requirements to ensure GLP-1 prescriptions meet clinical criteria before coverage is approved.
- Requiring participation in structured lifestyle intervention programs — such as nutrition counseling or exercise programs — as a condition of ongoing drug coverage.
- Establishing step therapy protocols that require patients to try lower-cost interventions before GLP-1 medications are covered.
- Working with pharmacy benefit managers (PBMs) to negotiate better rebates or preferred drug tiers for specific GLP-1 products.
- Tracking long-term health outcomes data to assess whether GLP-1 coverage is producing downstream savings in areas like cardiovascular claims, diabetes management, or reduced hospitalizations.
Looking Ahead: GLP-1 Costs Are Not Going Away
The data from Benefitfocus makes one thing unmistakably clear: GLP-1 medications are not a passing trend. With FDA approvals expanding, consumer awareness at an all-time high, and utilization rates still climbing, employers who treat this as a temporary problem are likely to be caught off guard by future budget cycles. A proactive, data-driven approach to GLP-1 benefit design is no longer optional for large self-insured plans — it is a financial necessity.
As the pharmaceutical pipeline continues to develop next-generation obesity and metabolic disease treatments, the conversation around GLP-1 spending will only grow more complex. Employers who begin building thoughtful, clinically grounded coverage policies today will be far better positioned to manage costs, support employee health, and maintain competitive benefit offerings in the years ahead.